Asston Pharmaceuticals Ltd
Incorporated in 2019, Asston Pharmaceuticals Ltd is in the business of manufacturing pharmaceutical products.[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | May 2025 | |
|---|---|---|---|---|
| Export Revenue (% of Total Sales) % ・Standalone data |
|
|||
| Pharmaceuticals Sales (% of Total Sales) % ・Standalone data |
||||
| Sierra Leone Revenue (% of Total Sales) % ・Standalone data |
||||
| Top 5 Customer Concentration (% of Revenue) % ・Standalone data |
||||
| Total Production Volume MT ・Standalone data |
||||
| Number of Registered Product Brands count ・Standalone data |
||||
| Order Book USD ・Standalone data |
||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Submitted Regulation 74(5) certificate for quarter ended 30 September 2026.
-
Announcement under Regulation 30 (LODR)-Change in Registered Office Address
- Board approved shifting registered office in Navi Mumbai, effective 15 October 2026.
-
Board Meeting Outcome for Outcome Of The Board Held On 13Th October, 2026.
- Board approved registered office shift within Navi Mumbai effective 15 October 2026.
-
Board Meeting Intimation for To Consider And Approve The Following Matters As Attached
- Board meets 13 Oct 2026 to consider registered office shift and auction property acquisition.
-
Announcement under Regulation 30 (LODR)-Change in Management
- Shareholders approved FY26 audited results, MD reappointment, auditor appointment, and director remuneration increases at AGM.
Business Overview:[1]
APL offers pharmaceutical products in the form of Tablet, Capsules, Syrup, Sachet and Injection (LVP and SVP). The company has WHO GMP approved manufacturing units for manufacturing
the entire products range and also has
a tie up with a NABL Accredited Laboratory.